|Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort|
KB Gecse, BD Lovász, K Farkas, J Banai, L Bene, B Gasztonyi, ...
Journal of Crohn's and Colitis 10 (2), 133-140, 2016
|Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in …|
LS Kiss, T Szamosi, T Molnar, P Miheller, L Lakatos, A Vincze, K Palatka, ...
Alimentary pharmacology & therapeutics 34 (8), 911-922, 2011
|New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a …|
M Papp, I Altorjay, N Dotan, K Palatka, I Foldi, J Tumpek, S Sipka, ...
American Journal of Gastroenterology 103 (3), 665-681, 2008
|Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype …|
M Papp, I Altorjay, GL Norman, Z Shums, K Palatka, Z Vitalis, I Foldi, ...
Inflammatory bowel diseases 13 (8), 984-992, 2007
|Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets|
B Mesko, S Poliskal, A Szegedi, Z Szekanecz, K Palatka, M Papp, L Nagy
BMC medical genomics 3 (1), 15, 2010
|Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis–experiences from a single center|
K Farkas, M Rutka, A Bálint, F Nagy, R Bor, Á Milassin, Z Szepes, ...
Expert opinion on biological therapy 15 (9), 1257-1262, 2015
|Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy|
T Molnár, PL Lakatos, K Farkas, F Nagy, Z Szepes, P Miheller, G Horváth, ...
Alimentary pharmacology & therapeutics 37 (2), 225-233, 2013
|Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not …|
PL Lakatos, I Altorjay, T Szamosi, K Palatka, Z Vitalis, J Tumpek, S Sipka, ...
Inflammatory bowel diseases 15 (3), 365-374, 2009
|Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis|
K Farkas, M Rutka, PA Golovics, Z Végh, BD Lovász, T Nyári, KB Gecse, ...
Journal of Crohn's and Colitis 10 (11), 1273-1278, 2016
|The association of reduced endothelium derived relaxing factor-NO production with endothelial damage and increased in vivo platelet activation in patients with diabetes mellitus|
M Huszka, M Kaplar, L Rejto, I Tornai, K Palatka, P Laszlo, M Udvardy
Thrombosis research 86 (2), 173-180, 1997
|Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease|
PL Lakatos, LS Kiss, K Palatka, I Altorjay, P Antal-Szalmas, E Palyu, ...
Inflammatory bowel diseases 17 (3), 767-777, 2011
|Changes in the expression and distribution of the inducible and endothelial nitric oxide synthase in mucosal biopsy specimens of inflammatory bowel disease|
K Palatka, Z Serfőző, Z Veréb, Z Hargitay, B Lontay, F Erdődi, G Bánfalvi, ...
Scandinavian journal of gastroenterology 40 (6), 670-680, 2005
|Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy|
K Farkas, PL Lakatos, F Nagy, Z Szepes, P Miheller, M Papp, K Palatka, ...
Scandinavian journal of gastroenterology 48 (12), 1394-1398, 2013
|Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease|
PL Lakatos, Z Czegledi, G David, Z Kispal, LS Kiss, K Palatka, T Kristof, ...
Journal of Crohn's and Colitis 4 (3), 283-290, 2010
|Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe-a Hungarian nationwide observational study|
P Miheller, PL Lakatos, G Horváth, T Molnár, T Szamosi, Z Czeglédi, ...
BMC gastroenterology 9 (1), 66, 2009
|NOD1 gene E266K polymorphism is associated with disease susceptibility but not with disease phenotype or NOD2/CARD15 in Hungarian patients with Crohn's disease|
T Molnár, P Hofner, F Nagy, PL Lakatos, S Fischer, L Lakatos, A Kovacs, ...
Digestive and Liver Disease 39 (12), 1064-1070, 2007
|DLG5 R30Q is not associated with IBD in hungarian IBD patients but predicts clinical response to steroids in crohn's disease|
PL Lakatos, S Fischer, K Claes, A Kovacs, T Molnar, I Altorjay, P Demeter, ...
Inflammatory bowel diseases 12 (5), 362-368, 2006
|Prediction of short-and medium-term efficacy of biosimilar infliximab therapy. Do trough levels and antidrug antibody levels or clinical and biochemical markers play the more …|
L Gonczi, Z Vegh, PA Golovics, M Rutka, KB Gecse, R Bor, K Farkas, ...
Journal of Crohn's and Colitis 11 (6), 697-705, 2017
|Haptoglobin polymorphisms are associated with Crohn’s disease, disease behavior, and extraintestinal manifestations in Hungarian patients|
M Papp, PL Lakatos, K Palatka, I Foldi, M Udvardy, J Harsfalvi, I Tornai, ...
Digestive diseases and sciences 52 (5), 1279-1284, 2007
|Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease|
B Mesko, S Poliska, A Váncsa, Z Szekanecz, K Palatka, Z Hollo, ...
Genome medicine 5 (6), 1-10, 2013